Lokelma
(Zirconium Cyclosilicate)Phase 3Small molecule
AstraZenecaLokelma is one of 9 small molecule programs targeting Hyperkalemia. It is currently in Phase 3.
1
Indications
1
Total Trials
0
Active Trials
8
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
14
Patents
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
16 competitors in Hyperkalemia
#DrugCompanyPhaseTrials
1Salbutamol
GSKApproved
Insulin 320
Novo NordiskApproved
Veltassa
VVifor Pharma
Phase 3
Sodium Valproate
AstraZenecaPhase 3
Insulin Regular
TThe University of Texas Medical Branch, Galveston
Approved
Lokelma
AstraZenecaPhase 3
Zirconium Silicate (ZS)
ZZS Pharma, Inc.
Phase 3
WS016
WWaterstone Pharmaceutical (Wuhan) Co., LTD.
Phase 2
Sodium Polystyrene Sulfonate
ZZS Pharma, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[4]
May 18, 2018
LOKELMA
NDA NDA207078
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Zirconium Cyclosilicate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company